Navigation Links
RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
Date:9/13/2008

as been used to treat the diarrhea and flushing associated with carcinoid syndrome.

The active ingredient in Sandostatin LAR Depot, octreotide acetate, was approved in the United States in October 1988. In November 1998, the FDA approved the long-acting formulation of octreotide acetate which Novartis markets as Sandostatin LAR Depot. Through more than a decade, and 600,000 patient years of experience, Sandostatin LAR Depot has achieved a long-standing track record of sustained efficacy and a well-established safety profile.

Sandostatin LAR Depot important safety information

Adverse reactions identified in clinical studies include nausea, abdominal pain, gas, constipation, vomiting, pain on injection, high or low blood sugar levels and slow or irregular heart rate. Many patients developed gallstones, although few patients required treatment.

Disclaimer

The foregoing release contains forward-looking statements that can be identified by terminology such as "potential", "to confirm", "promise", "proposed", "promising", "may", "will", or similar expressions, or by express or implied discussions regarding potential marketing approvals for RAD001 or regarding potential future revenues from RAD001. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of the Company regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with RAD001 to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that RAD001 will be approved for sale in any market. Nor can there be any guarantee that RAD001 will achieve any particular levels of revenue in the future. In particular, management's expectations regarding RAD001 could be affected by, among other things, unexpected clinical trial results, including unexpected new clinical data and unexpe
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. RAD001 Granted Priority Review in the US Based on Potential to Fill Unmet Medical Need in Patients With Advanced Kidney Cancer
2. Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
3. RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
4. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
5. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
6. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
7. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
8. An Open Letter to Parents, Students, School Administrators, & Health Care Officials from Soapopular(R)
9. Results Published in the Journal Cancer Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma
10. Phase 3 Results for Alogliptin Demonstrated Significant Blood Sugar Reductions in Monotherapy and Four Add-on Therapy Studies
11. Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... Cambrex Corporation (NYSE: CBM ) reports results for the ... , Sales increased 18% compared to the first ... driven by Innovator products and Controlled Substances. , EBITDA ... quarter of 2014. , GAAP Diluted EPS from continuing ... year and Adjusted Diluted EPS was $0.29 compared to $0.07 ...
(Date:4/30/2015)... Calif., April 30, 2015 Abaxis, Inc. (NasdaqGS: ... blood analysis systems, today reported financial results for the ... Fourth quarter and fiscal 2015 overview: ... the fourth quarter, up 33% over last year,s comparable ... year-over-year. , Diluted EPS of $0.50 for the ...
(Date:4/30/2015)... 30, 2015  IRIDEX Corporation (NASDAQ: IRIX ) ... 2015 financial results after the market closes on ... release, the Company will host a conference call with ... on Thursday, May 7, 2015 to ... developments. Interested parties may access the live ...
Breaking Medicine Technology:Cambrex Reports First Quarter 2015 Financial Results 2Cambrex Reports First Quarter 2015 Financial Results 3Cambrex Reports First Quarter 2015 Financial Results 4Cambrex Reports First Quarter 2015 Financial Results 5Cambrex Reports First Quarter 2015 Financial Results 6Cambrex Reports First Quarter 2015 Financial Results 7Cambrex Reports First Quarter 2015 Financial Results 8Cambrex Reports First Quarter 2015 Financial Results 9Cambrex Reports First Quarter 2015 Financial Results 10Cambrex Reports First Quarter 2015 Financial Results 11Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 2Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 3Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 4Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 5Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 6Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 7Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 8Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 9Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 10Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 11Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 12Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 13Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 14Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 15Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 16Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 17Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 18Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 19Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 20Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 21Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 22Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 23Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 24IRIDEX Announces First Quarter 2015 Conference Call and Release Date 2
... CarePoint Partners (CarePoint) today announced that ... home infusion pharmacy services in Austin, Texas and ... Atlanta, Georgia area. The Austin location complements CarePoint,s ... to grow its southeastern footprint with this expansion ...
... PharMEDium Healthcare Corporation has become an Industry Supporter of ... of a new Corporate Supporter program available to pharmaceutical, ... N. Jonas, PharMEDium Chairman and CEO commented, "We are ... field through leadership, education and research.  As a leading ...
Cached Medicine Technology:CarePoint Partners Expands Texas Presence and Opens Georgia Market With Acquisition of Premier Infusion 2PharMEDium Becomes a Corporate Supporter of the American Society of Anesthesiologists (ASA) 2
(Date:5/1/2015)... May 01, 2015 Pioneer Millworks, the ... the latest in their reclaimed wood products at the ... Jacob Javits Center in NYC this May. Their newest ... bring much anticipated texture and color to North America's ... explosion of texture and color in the design world ...
(Date:5/1/2015)... RESTON, Va. (PRWEB) May 01, 2015 ... the nation’s leading nonprofit authority on the use of ... served as a key contributing resource to the United ... the use of electronically readable cards in Medicare. The ... Beneficiaries and Providers ” was released to the public ...
(Date:5/1/2015)... 2015 Hope For The Warriors® thanks ... For The Warriors® and military families. All American Ford ... For The Warriors®, a national nonprofit dedicated to restoring ... restoring hope for our service members and our military ... Ford collected and matched small autograph fee from fans ...
(Date:5/1/2015)... (PRWEB) May 01, 2015 The Quail Creek ... American Cancer Society. Since 2001, the Quail Creek Relay team ... team host events throughout the year, including their biggest event, ... Golf Ball Drop. , Quail Creek Relay for Life ... battling cancer. Kate Kerwin, fitness director, states, “I was hooked ...
(Date:5/1/2015)... May 01, 2015 Digital technology and ... pregnant women between prenatal appointments, a preliminary study ... a small sample of low-risk pregnant women, will be ... Washington University Medical Faculty Associates at the 2015 American ... Scientific Meeting, May 2-6. The digital technology used was ...
Breaking Medicine News(10 mins):Health News:Intensely Textured Reclaimed Wood to be Unveiled at ICFF in NYC by Pioneer Millworks 2Health News:Intensely Textured Reclaimed Wood to be Unveiled at ICFF in NYC by Pioneer Millworks 3Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 2Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 3Health News:All American Ford Presents Donation to Nonprofit Hope For The Warriors 2Health News:Quail Creek Country Club’s Relay for Life Team Raised Over $89,000 for American Cancer Society 2Health News:Mobile Technology May Be Effective in Monitoring Pregnant Women Between Office Visits, Study Shows 2Health News:Mobile Technology May Be Effective in Monitoring Pregnant Women Between Office Visits, Study Shows 3
... new ways of getting the most healthful fats into ... are associated with chronic diseases, while their neighbours, the ... includes some of each. ,The American Heart ... like sardines, salmon and tuna. Researchers at Texas University ...
... California report that acupuncture may help some cancer patients ... of treatment.//Their study, included mainly patients with head and ... the ear and index finger recuperated dry mouth in ... in China more than 2,000 years ago, acupuncture involves ...
... development at Sandia National Laboratories can identify the fatty ... five minutes. //Sandia's Laboratory Directed Research and Development program ... by Sandia Corporation, a Lockheed Martin company, for the ... in all living organisms with cell membranes. Analyses of ...
... Amorphous calcium phosphate is showing great covenant in ... Institute of Standards and Technology at Ohio.//This ACP ... a researcher at OSU. “It’s more soluble than ... convert to the stable dental mineral hydroxyapatite, which ...
... deCODE genetics and Iceland's National University Hospital, ascertained that ... by more than 62 per cent.//,Endometriosis is a painful ... in the lining of the uterus, develops outside the ... in the abdominal cavity, but still responds to the ...
... diet mean people today are more at risk of developing ... University of Newcastle believe that changes to the way food ... agents. ,The researchers are working on a study ... cancer. They are carrying out two trials on people with ...
Cached Medicine News:Health News:Acupuncture to bring relief to patients with dry mouth 2
... VelaSmooth is the first and ... with the revolutionary elos combined ... Frequency and Infrared Light ... suction to reduce the appearance ...
... result of DEKA's new technology ... different methods capable of restoring,a ... treatment is designed to dramatically ... the combined action of a ...
... SilkPeel Dermalinfusion is the ... of deliver a topical dermaceutical ... effectively treats all skin types ... of dermatological conditions including hyperpigmentation, ...
... Novalis offers the Clareon to practices that ... treatment speed and efficacy. The versatility of ... a wide range of treatments that would ... never need to worry about obsolescence because ...
Medicine Products: